Living dossier · Competitive landscape

PARP1/2 in Ovarian cancer

Primary identifiers: 8
Sponsors tracked: 7
Evidence types: 2 of 3
Last refreshed: 2026-07-28 · monthly

MightyRayn panel synthesis

OmniRayn’s reading of this landscape — our interpretation, not a registry fact

A mature market where the interesting activity has moved downstream of approval. The registry shows the field working three problems the first generation left behind: extending benefit past the BRCA-mutated population into BRCA wild-type disease, combining with anti-angiogenics or MEK inhibition, and rechallenging patients who have already progressed on a PARP inhibitor. The literature is blunt that a large share of patients develop resistance, largely by restoring homologous recombination, and points at ATR, WEE1 and POLQ as the routes being explored around it. Read this as the resistance landscape rather than the approval landscape — that is where the record is actually moving.

Programs and primary evidence

Sponsor	Asset	Phase	Mechanism	Primary source
AstraZeneca	Olaparib (SOLO-1)	3	PARP inhibitor maintenance monotherapy	NCT01844986 — Phase 3 maintenance in BRCA-mutated advanced ovarian cancer after first-line platinum chemotherapy
AstraZeneca	Olaparib (MONO-OLA1)	3	PARP inhibitor maintenance beyond the BRCA-mutated population	NCT04884360 — Phase 3 maintenance in BRCA wild-type high-grade serous or endometrioid ovarian cancer
Tesaro	Niraparib (PRIMA)	3	PARP inhibitor front-line maintenance	NCT02655016 — Phase 3 maintenance following response to front-line platinum-based chemotherapy
AGO Study Group	Niraparib +/- bevacizumab	3	PARP inhibitor with anti-angiogenic combination	NCT05009082 — Randomised Phase 3 of niraparib versus niraparib plus bevacizumab after carboplatin-taxane chemotherapy
Institute of Cancer Research, United Kingdom	Niraparib + SBRT (SOPRANO)	2	PARP inhibitor after prior PARP inhibitor therapy, with stereotactic radiotherapy	NCT05990192 — Stereotactic radiotherapy alone or followed by niraparib for oligoprogression after PARP inhibitor therapy
MedSIR	Niraparib rechallenge (ANALLISA)	2	PARP inhibitor rechallenge after oligometastatic progression	NCT06180356 — Phase 2 of niraparib rechallenge after surgery in patients with oligometastatic progression
University of Nottingham / University of Oxford	review	—	restored homologous recombination, replication fork stability, PARP1/2 alteration	10.1016/j.dnarep.2025.103830 — Mechanisms of PARP inhibitor resistance in ovarian cancer and the ATR, WEE1 and POLQ strategies proposed to overcome them
Princess Margaret Cancer Centre	review	—	reversion of homologous repair deficiency to proficiency	10.1136/ijgc-2022-003698 — Overcoming PARP inhibitor resistance, including re-sensitisation strategies and patient selection

Method and limits

Programs are enumerated from primary registries (ClinicalTrials.gov, PubMed). A program appears here only if a primary record links this target to this indication as a therapeutic hypothesis — associations and risk markers are excluded by design.
Every claim above carries the identifier it rests on. We report what the record states; we do not assert efficacy, and computational findings are pending wet-lab confirmation.
Absence is not evidence of absence: unregistered, non-US and stealth-stage programs are not visible to these sources.
This page refreshes monthly (no net-new primary entity in 481 days). Mechanism classifications are our reading of the public record and may be revised.

Want the analysis behind this landscape?

The public page is the map. The full dossier adds differentiation analysis, kill-tests and the whitespace read for this target — the parts we do not publish.

Request the full dossier All landscapes